Accelerated Biosciences

Accelerated Biosciences, founded in 2014, is a private, pre-revenue biotech platform company based in San Diego, CA, with a corporate presence in Philadelphia, PA. Its core innovation is a patented, ethically sourced human trophoblast stem cell (hTSC) platform, which serves as a versatile and scalable starting material for regenerative medicine. The company operates a partnership-driven business model, licensing its hTSCs, derived induced pluripotent stem cells (iPSCs), exosomes, and genetically engineered platforms (GEMS, CHO-GEMS) to biopharma partners and research institutions to accelerate their therapeutic development. Its strategy focuses on de-risking early-stage development for partners by providing clear IP, GMP-eligible cell lines, and standardized processes.

Patented platform based on ethically sourced human trophoblast stem cells (hTSCs). The platform includes native hTSC lines, hTSC-derived induced pluripotent stem cells (iPSCs), hTSC-derived exosomes, and genetically engineered systems (GEMS, CHO-GEMS) for precision cell engineering and antibody production.

Accelerated competes with established iPSC technology companies (e.g., Fate Therapeutics, Century Therapeutics, CDI), embryonic stem cell platform firms, and other stem cell sourcing technologies. Its differentiation lies in the ethical provenance, native immune privilege, and claimed functional advantages of its hTSCs, as well as its freedom-to-operate position outside core Yamanaka factor IP.